A cohort study was launched within the single arm phase 1b trial (NCT03299946) exploring the combination of cabozantinib (TKIs) and nivolumab (anti-PD-1) in locally advanced HCC patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.